{"success":true,"data":{"pressRelease":{"id":"63602","rtpr_id":"nGNX1DmnQj","ticker":"SGP","exchange":"NASDAQ","all_tickers":["SGP"],"title":"SpyGlass Pharma Appoints Shannon Treviño as General Counsel","author":"Globe Newswire","published_at":"2026-06-15T12:00:00.480Z","article_body":"ALISO VIEJO, Calif., June 15, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc.\n(Nasdaq: SGP) (SpyGlass Pharma or Company), a late-stage biopharmaceutical\ncompany, today announced the appointment of Shannon Treviño as general\ncounsel. Ms. Treviño brings significant business-oriented legal experience\nand leadership that results in operating excellence for publicly traded\ncompanies at various stages of growth.\n\n“We are delighted to welcome Shannon to our growing team. She is a proven\nleader with a track record of guiding complex organizations through periods of\ngrowth,” said Patrick Mooney, CEO of SpyGlass Pharma. “The team we are\nbuilding at SpyGlass is second to none, and I am confident that Shannon’s\nexperiences will be invaluable as we continue to advance our BIM-IOL System\nthrough its Phase 3 trials and towards a potential commercialization.”\n\nMs. Treviño is a strategic legal executive with experience in corporate, M&A,\nand securities law in the healthcare industry. Most recently serving as\nGeneral Counsel and Corporate Secretary at Inari Medical, Ms. Treviño oversaw\nthe legal and compliance functions and helped guide the company through its\n$4.9 billion acquisition by Stryker. She also was instrumental in Inari's\nacquisition of LimFlow and its subsequent integration. Prior to Inari, she\nserved as an attorney at Sugg Law Group, where she advised early and\ngrowth-stage companies on governance, commercial contracts, capital formation,\nand M&A transactions. She also spent eight years as a Clinical Professor and\nDirector of the Transactional Lawyering Institute at Loyola Marymount\nUniversity’s Law School, where she taught courses on venture capital, M&A\nnegotiations, and in-house lawyering, and co-authored two editions of a\ntextbook on startup financing.\n\nEarlier in her career, Shannon was a corporate attorney at Latham & Watkins\nLLP from 2006 to 2015. Ms. Treviño holds a J.D., summa cum laude, from LMU\nLoyola Law School and an A.B. from Princeton University.\n\n“It is a pleasure to join SpyGlass at such an exciting time for the company\nas its Phase 3 trials are enrolling and the company plans for a potential\ncommercial launch of the innovative BIM-IOL System,” said Ms. Treviño. “I\nlook forward to collaborating with the entire SpyGlass Pharma team and\nsupporting our ongoing efforts to transform the treatment paradigm for\npatients living with chronic eye conditions.”\n\nAbout the Bimatoprost Drug Pad-IOL System\n\nSpyGlass Pharma’s lead product candidate, the Bimatoprost Drug Pad-IOL\nSystem (BIM-IOL System), comprising novel, proprietary non-bioerodible drug\npads attached to its intraocular lens, was designed to be implanted during\nroutine cataract surgery to reduce elevated intraocular pressure (IOP) in\npatients who have either open-angle glaucoma (OAG) or ocular hypertension\n(OHT). The BIM-IOL System is designed to consistently deliver three years of\nbimatoprost, a prostaglandin analog approved for topical use by the U.S. Food\nand Drug Administration (FDA) in 2001, for the reduction of elevated IOP in\npatients with OAG or OHT.\n\nThe Company initiated two registrational Phase 3 clinical trials of the\nBIM-IOL System and continues long-term follow-up of patients in the Phase 1/2\nstudy investigating the safety and efficacy of the BIM-IOL System. SpyGlass\nPharma plans to work with the FDA to advance the program through completion of\nPhase 3 clinical trials, new drug application submission, and ultimately to\npotential FDA approval.\n\nAbout SpyGlass Pharma\n\nSpyGlass Pharma is a late-stage biopharmaceutical company dedicated to\ntransforming the treatment paradigm for patients living with chronic eye\nconditions through long-acting, sustained drug delivery of approved medicines.\nThe Company’s mission is to significantly improve the lives of patients with\nchronic eye conditions by developing durable drug delivery solutions that can\nempower patients and surgeons with confidence in long-term disease control and\nvision preservation.\n\nThe SpyGlass Pharma platform, a novel, non-bioerodible drug delivery\ntechnology, is designed to be used with various well-established, approved\nmedicines, including bimatoprost and other small molecules, providing\nflexibility to potentially treat a range of conditions in the front and back\nof the eye.\n\nThe Company was founded in 2019 by Malik Y. Kahook, M.D. and Glenn Sussman to\nsolve the lack of ophthalmic innovations that capitalize on durable treatment\noptions. The SpyGlass Pharma platform was originally developed in the Sue\nAnschutz-Rodgers Eye Center at the University of Colorado Anschutz School of\nMedicine.\n\nForward-looking Statements\n\nThis press release contains forward-looking statements within the meaning of\nSection 27A of the Securities Act of 1933, as amended, and Section 21E of the\nSecurities Exchange Act of 1934, as amended. All statements in this press\nrelease that are not purely historical are forward-looking statements,\nincluding, but not limited to, statements regarding: the potential benefits\nand impact of the BIM-IOL System on patients, anticipated presentation of\nadditional data, and SpyGlass Pharma’s plans relating to the clinical\ndevelopment of the BIM-IOL System towards potential commercial launch after\nFDA approval. The forward-looking statements contained herein are based upon\nSpyGlass Pharma’s current expectations and involve assumptions that may\nnever materialize or may prove to be incorrect. These forward-looking\nstatements are neither promises nor guarantees and are subject to a variety of\nrisks and uncertainties, including those set forth in the Risk Factors section\nof the Company’s Quarterly Report on Form 10-Q for the three month period\nended March 31, 2026 filed with the Securities and Exchange Commission on May\n14, 2026, and in similar disclosures set forth in the other documents that\nSpyGlass Pharma has filed and may file from time to time with the SEC. These\nforward-looking statements are made as of the date of this press release, and\nSpyGlass Pharma assumes no obligation to update or revise any forward-looking\nstatements, whether as a result of new information, future events, or\notherwise, except as required by law. SpyGlass Pharma’s views in these\nforward-looking statements should not be relied as representing the\nCompany’s views as of any date subsequent to the date of this press release.\n\nMedia Contact:\nNami Surendranath\n(402) 507-6757\nnsurendranath@dnacommunications.com\n\nInvestor Contact:\nAmi Bavishi or Nick Colangelo\nGilmartin Group LLC\ninvestors@spyglasspharma.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/fe0fc2c2-1623-4d3f-94bb-41782201a1e6)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX1DmnQj","title":"SpyGlass Pharma Appoints Shannon Treviño as General Counsel","author":"Globe Newswire","ticker":"SGP","created":"2026-06-15T12:00:00.480Z","tickers":["SGP"],"exchange":"NASDAQ","article_body":"ALISO VIEJO, Calif., June 15, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc.\n(Nasdaq: SGP) (SpyGlass Pharma or Company), a late-stage biopharmaceutical\ncompany, today announced the appointment of Shannon Treviño as general\ncounsel. Ms. Treviño brings significant business-oriented legal experience\nand leadership that results in operating excellence for publicly traded\ncompanies at various stages of growth.\n\n“We are delighted to welcome Shannon to our growing team. She is a proven\nleader with a track record of guiding complex organizations through periods of\ngrowth,” said Patrick Mooney, CEO of SpyGlass Pharma. “The team we are\nbuilding at SpyGlass is second to none, and I am confident that Shannon’s\nexperiences will be invaluable as we continue to advance our BIM-IOL System\nthrough its Phase 3 trials and towards a potential commercialization.”\n\nMs. Treviño is a strategic legal executive with experience in corporate, M&A,\nand securities law in the healthcare industry. Most recently serving as\nGeneral Counsel and Corporate Secretary at Inari Medical, Ms. Treviño oversaw\nthe legal and compliance functions and helped guide the company through its\n$4.9 billion acquisition by Stryker. She also was instrumental in Inari's\nacquisition of LimFlow and its subsequent integration. Prior to Inari, she\nserved as an attorney at Sugg Law Group, where she advised early and\ngrowth-stage companies on governance, commercial contracts, capital formation,\nand M&A transactions. She also spent eight years as a Clinical Professor and\nDirector of the Transactional Lawyering Institute at Loyola Marymount\nUniversity’s Law School, where she taught courses on venture capital, M&A\nnegotiations, and in-house lawyering, and co-authored two editions of a\ntextbook on startup financing.\n\nEarlier in her career, Shannon was a corporate attorney at Latham & Watkins\nLLP from 2006 to 2015. Ms. Treviño holds a J.D., summa cum laude, from LMU\nLoyola Law School and an A.B. from Princeton University.\n\n“It is a pleasure to join SpyGlass at such an exciting time for the company\nas its Phase 3 trials are enrolling and the company plans for a potential\ncommercial launch of the innovative BIM-IOL System,” said Ms. Treviño. “I\nlook forward to collaborating with the entire SpyGlass Pharma team and\nsupporting our ongoing efforts to transform the treatment paradigm for\npatients living with chronic eye conditions.”\n\nAbout the Bimatoprost Drug Pad-IOL System\n\nSpyGlass Pharma’s lead product candidate, the Bimatoprost Drug Pad-IOL\nSystem (BIM-IOL System), comprising novel, proprietary non-bioerodible drug\npads attached to its intraocular lens, was designed to be implanted during\nroutine cataract surgery to reduce elevated intraocular pressure (IOP) in\npatients who have either open-angle glaucoma (OAG) or ocular hypertension\n(OHT). The BIM-IOL System is designed to consistently deliver three years of\nbimatoprost, a prostaglandin analog approved for topical use by the U.S. Food\nand Drug Administration (FDA) in 2001, for the reduction of elevated IOP in\npatients with OAG or OHT.\n\nThe Company initiated two registrational Phase 3 clinical trials of the\nBIM-IOL System and continues long-term follow-up of patients in the Phase 1/2\nstudy investigating the safety and efficacy of the BIM-IOL System. SpyGlass\nPharma plans to work with the FDA to advance the program through completion of\nPhase 3 clinical trials, new drug application submission, and ultimately to\npotential FDA approval.\n\nAbout SpyGlass Pharma\n\nSpyGlass Pharma is a late-stage biopharmaceutical company dedicated to\ntransforming the treatment paradigm for patients living with chronic eye\nconditions through long-acting, sustained drug delivery of approved medicines.\nThe Company’s mission is to significantly improve the lives of patients with\nchronic eye conditions by developing durable drug delivery solutions that can\nempower patients and surgeons with confidence in long-term disease control and\nvision preservation.\n\nThe SpyGlass Pharma platform, a novel, non-bioerodible drug delivery\ntechnology, is designed to be used with various well-established, approved\nmedicines, including bimatoprost and other small molecules, providing\nflexibility to potentially treat a range of conditions in the front and back\nof the eye.\n\nThe Company was founded in 2019 by Malik Y. Kahook, M.D. and Glenn Sussman to\nsolve the lack of ophthalmic innovations that capitalize on durable treatment\noptions. The SpyGlass Pharma platform was originally developed in the Sue\nAnschutz-Rodgers Eye Center at the University of Colorado Anschutz School of\nMedicine.\n\nForward-looking Statements\n\nThis press release contains forward-looking statements within the meaning of\nSection 27A of the Securities Act of 1933, as amended, and Section 21E of the\nSecurities Exchange Act of 1934, as amended. All statements in this press\nrelease that are not purely historical are forward-looking statements,\nincluding, but not limited to, statements regarding: the potential benefits\nand impact of the BIM-IOL System on patients, anticipated presentation of\nadditional data, and SpyGlass Pharma’s plans relating to the clinical\ndevelopment of the BIM-IOL System towards potential commercial launch after\nFDA approval. The forward-looking statements contained herein are based upon\nSpyGlass Pharma’s current expectations and involve assumptions that may\nnever materialize or may prove to be incorrect. These forward-looking\nstatements are neither promises nor guarantees and are subject to a variety of\nrisks and uncertainties, including those set forth in the Risk Factors section\nof the Company’s Quarterly Report on Form 10-Q for the three month period\nended March 31, 2026 filed with the Securities and Exchange Commission on May\n14, 2026, and in similar disclosures set forth in the other documents that\nSpyGlass Pharma has filed and may file from time to time with the SEC. These\nforward-looking statements are made as of the date of this press release, and\nSpyGlass Pharma assumes no obligation to update or revise any forward-looking\nstatements, whether as a result of new information, future events, or\notherwise, except as required by law. SpyGlass Pharma’s views in these\nforward-looking statements should not be relied as representing the\nCompany’s views as of any date subsequent to the date of this press release.\n\nMedia Contact:\nNami Surendranath\n(402) 507-6757\nnsurendranath@dnacommunications.com\n\nInvestor Contact:\nAmi Bavishi or Nick Colangelo\nGilmartin Group LLC\ninvestors@spyglasspharma.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/fe0fc2c2-1623-4d3f-94bb-41782201a1e6)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-06-15T12:00:01.3760519Z","server_sent_at_ms":1781524801376},"received_at":"2026-06-15T12:00:01.522Z","source_url":null},"analysis":{"id":"53026","press_release_id":"63602","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"executive_change","narrative":"SpyGlass Pharma appointed Shannon Treviño as General Counsel, effective immediately.\n\nTreviño previously served as General Counsel at Inari Medical, where she helped guide the company through its $4.9 billion acquisition by Stryker.\n\nShe joins SpyGlass as the company advances its lead asset, the BIM-IOL System, through Phase 3 clinical trials toward potential FDA approval.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Routine executive hire; no material market impact."},"keyFigures":{"customDimensions":{"inari_acquisition_value":"$4.9 billion"}},"quotedText":"We are delighted to welcome Shannon to our growing team. She is a proven leader with a track record of guiding complex organizations through periods of growth","namedEntities":{"people":[{"name":"Shannon Treviño","role":"General Counsel"},{"name":"Patrick Mooney","role":"CEO"},{"name":"Malik Y. Kahook","role":"Co-founder"},{"name":"Glenn Sussman","role":"Co-founder"}],"products":["BIM-IOL System","Bimatoprost Drug Pad-IOL System"],"companies":[{"name":"SpyGlass Pharma, Inc.","ticker":"SGP"},{"name":"Inari Medical","relationship":"former employer of appointee"},{"name":"Stryker","relationship":"acquirer of Inari Medical"},{"name":"LimFlow","relationship":"acquired by Inari Medical"},{"name":"Sugg Law Group","relationship":"former employer of appointee"},{"name":"Loyola Marymount University","relationship":"former employer of appointee"},{"name":"Latham & Watkins LLP","relationship":"former employer of appointee"}],"dollarAmounts":[{"amount":"$4.9 billion","context":"acquisition value of Inari Medical by Stryker"}]},"materialImpact":{"score":2,"reasoning":"Appointment of General Counsel is a routine corporate governance update. While the appointee has strong credentials (ex-Inari Medical), this is not a CEO/CFO change or a binary regulatory event. It signals organizational stability but does not materially alter near-term valuation drivers."},"tickerRelevance":{"others":[{"ticker":"SYK","relevance":"mentioned"}],"primary":"SGP"},"globalImportance":15,"audienceRelevance":10,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"routine_executive_hire","sectorWeight":"biotech","householdBrandBoost":0}},"event_type":"executive_change","event_type_secondary":null,"sentiment":"neutral","material_impact_score":2,"narrative":"SpyGlass Pharma appointed Shannon Treviño as General Counsel, effective immediately.\n\nTreviño previously served as General Counsel at Inari Medical, where she helped guide the company through its $4.9 billion acquisition by Stryker.\n\nShe joins SpyGlass as the company advances its lead asset, the BIM-IOL System, through Phase 3 clinical trials toward potential FDA approval.","key_figures":{"customDimensions":{"inari_acquisition_value":"$4.9 billion"}},"named_entities":{"people":[{"name":"Shannon Treviño","role":"General Counsel"},{"name":"Patrick Mooney","role":"CEO"},{"name":"Malik Y. Kahook","role":"Co-founder"},{"name":"Glenn Sussman","role":"Co-founder"}],"products":["BIM-IOL System","Bimatoprost Drug Pad-IOL System"],"companies":[{"name":"SpyGlass Pharma, Inc.","ticker":"SGP"},{"name":"Inari Medical","relationship":"former employer of appointee"},{"name":"Stryker","relationship":"acquirer of Inari Medical"},{"name":"LimFlow","relationship":"acquired by Inari Medical"},{"name":"Sugg Law Group","relationship":"former employer of appointee"},{"name":"Loyola Marymount University","relationship":"former employer of appointee"},{"name":"Latham & Watkins LLP","relationship":"former employer of appointee"}],"dollarAmounts":[{"amount":"$4.9 billion","context":"acquisition value of Inari Medical by Stryker"}]},"model_name":"qwen3_6_27b_awq","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-06-15T12:05:07.830Z","global_importance":15,"audience_relevance":10,"importance_components":{"tickerTier":"small-cap","eventGravity":"routine_executive_hire","sectorWeight":"biotech","householdBrandBoost":0}},"durationMs":25344,"modelName":"george-droid-qwen-72b"}}